<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002294</url>
  </required_header>
  <id_info>
    <org_study_id>012A</org_study_id>
    <secondary_id>056-114A</secondary_id>
    <nct_id>NCT00002294</nct_id>
  </id_info>
  <brief_title>A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS</brief_title>
  <official_title>Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare the safety and effectiveness of fluconazole with that of placebo as maintenance&#xD;
      treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Meningitis, Cryptococcal</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiviral therapy (e.g., zidovudine).&#xD;
&#xD;
          -  Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia&#xD;
             (PCP).&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.&#xD;
&#xD;
        Patients must be oriented to person, place, and time and able to give written informed&#xD;
        consent.&#xD;
&#xD;
          -  Patients must have had an acute episode of cryptococcal meningitis that was documented&#xD;
             by recovery and identification of cryptococcus from lumbar cerebrospinal fluid (CSF)&#xD;
             culture within 4 months of study entry.&#xD;
&#xD;
          -  Adequate therapy will consist of 6 - 16 weeks of treatment with amphotericin B alone,&#xD;
             amphotericin B + oral flucytosine, or a period of the combination followed by&#xD;
             amphotericin alone. Adequate regimens will include:&#xD;
&#xD;
          -  A minimum total amphotericin B dose of 2 grams as monotherapy.&#xD;
&#xD;
          -  6 weeks of flucytosine at 150 mg/kg/day (or levels of 20 to 100 mcg/ml demonstrated)&#xD;
             plus amphotericin B at an average daily dose of at least 0.3 mg/kg/day or to a total&#xD;
             dose of 1 gram.&#xD;
&#xD;
          -  After a shorter period of the combination amphotericin/flucytosine therapy, an&#xD;
             additional Y grams of amphotericin B monotherapy will make therapy adequate where Y =&#xD;
             2 gm-(X weeks combination therapy / 3 weeks).&#xD;
&#xD;
          -  For example, a patient who received 3 weeks of combination followed by amphotericin&#xD;
             alone would need an additional 2 gm - 3 weeks/3 weeks = 1 gm of amphotericin B.&#xD;
&#xD;
          -  Patients need not be receiving amphotericin B at the time of randomization but must&#xD;
             begin study maintenance therapy within 3 weeks of cessation of primary amphotericin B&#xD;
             therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiviral therapy (e.g., zidovudine (AZT)).&#xD;
&#xD;
          -  Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia&#xD;
             (PCP).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Clinical evidence of acute or chronic meningitis based upon any etiology other than&#xD;
             cryptococcosis.&#xD;
&#xD;
          -  History of allergy or intolerance of imidazoles, azoles, or amphotericin B.&#xD;
&#xD;
          -  Moderate or severe liver disease.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Intrathecal amphotericin B.&#xD;
&#xD;
          -  Coumarin-type anticoagulants.&#xD;
&#xD;
          -  Oral hypoglycemics.&#xD;
&#xD;
          -  Barbiturates.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Immunostimulants.&#xD;
&#xD;
          -  Investigational drugs or approved (licensed) drugs for investigational indications.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Lymphocyte replacement.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Clinical evidence of acute or chronic meningitis based upon any etiology other than&#xD;
             cryptococcosis.&#xD;
&#xD;
          -  History of allergy or intolerance of imidazoles, azoles, or amphotericin B.&#xD;
&#xD;
          -  Moderate or severe liver disease defined by specific lab values.&#xD;
&#xD;
          -  Inability to take oral medications reliably.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Intrathecal amphotericin B.&#xD;
&#xD;
          -  Coumarin-type anticoagulants.&#xD;
&#xD;
          -  Oral hypoglycemics.&#xD;
&#xD;
          -  Barbiturates.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Immunostimulants.&#xD;
&#xD;
          -  Investigational drugs or approved (licensed) drugs for investigational indications.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Lymphocyte replacement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr Robert Larsen</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Med Ctr</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Paul Rothman</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Univ School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Cryptococcosis</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

